Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy | Zendy

Aciel A. Shaheen | Zendy; Ismail Hader | Zendy; Zakaria Aqel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy

Author(s) -

Aciel A. Shaheen,

Ismail Hader,

Zakaria Aqel

Publication year - 2021

Publication title -

case reports in gastrointestinal medicine

Language(s) - English

Resource type - Journals

eISSN - 2090-6528

pISSN - 2090-6536

DOI - 10.1155/2021/5213876

Subject(s) - medicine , secukinumab , ustekinumab , anakinra , interleukin 23 , inflammatory bowel disease , immunology , psoriatic arthritis , crohn's disease , psoriasis , proinflammatory cytokine , ulcerative colitis , ileitis , interleukin 17 , immune system , disease , tumor necrosis factor alpha , infliximab , inflammation

Inflammatory bowel disease (IBD) and psoriasis are chronic inflammatory immune-mediated diseases. The interleukin-23- (IL23-) T helper (Th)17 pathway has been implicated in their pathogenesis, with multiple biologic therapies targeting this pathway. IL-17, the main proinflammatory cytokine produced by (TH)17, has been targeted by antibodies and IL-17 receptor blockers with favorable outcomes in treating psoriasis and psoriatic arthritis. However, their role in IBD is unpredictable as studies reported worsening of IBD with agents targeting IL-17 and rare case reports with new-onset IBD. We present a case of Crohn's-like severe terminal ileitis and worsening diverticulitis complicated by intestinal perforation requiring total parenteral nutrition shortly after being started on secukinumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research